Compare AANJANEYA LIFECARE with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS ASTRAZENECA PHARMA DR. DATSONS LABS/
ASTRAZENECA PHARMA
 
P/E (TTM) x -10.9 93.4 - View Chart
P/BV x 0.2 26.3 0.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
ASTRAZENECA PHARMA
Mar-18
DR. DATSONS LABS/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,278 9.8%   
Low Rs31883 3.5%   
Sales per share (Unadj.) Rs133.0228.4 58.2%  
Earnings per share (Unadj.) Rs0.210.4 1.5%  
Cash flow per share (Unadj.) Rs6.616.3 40.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.898.8 130.4%  
Shares outstanding (eoy) m31.6625.00 126.6%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.64.7 12.4%   
Avg P/E ratio x516.1104.2 495.2%  
P/CF ratio (eoy) x11.866.4 17.8%  
Price / Book Value ratio x0.610.9 5.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,47727,008 9.2%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m561,535 3.6%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m4,2115,710 73.7%  
Other income Rs m79123 64.2%   
Total revenues Rs m4,2895,833 73.5%   
Gross profit Rs m569463 122.8%  
Depreciation Rs m204147 138.7%   
Interest Rs m4300-   
Profit before tax Rs m13438 2.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6179 3.4%   
Profit after tax Rs m5259 1.9%  
Gross profit margin %13.58.1 166.6%  
Effective tax rate %48.040.8 117.6%   
Net profit margin %0.14.5 2.5%  
BALANCE SHEET DATA
Current assets Rs m6,8523,209 213.5%   
Current liabilities Rs m6,7112,070 324.3%   
Net working cap to sales %3.320.0 16.8%  
Current ratio x1.01.6 65.8%  
Inventory Days Days16172 222.4%  
Debtors Days Days31835 912.0%  
Net fixed assets Rs m3,673790 464.8%   
Share capital Rs m31750 633.2%   
"Free" reserves Rs m3,7612,419 155.5%   
Net worth Rs m4,0782,469 165.1%   
Long term debt Rs m1,6710-   
Total assets Rs m12,6334,605 274.3%  
Interest coverage x1.0NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.31.2 26.9%   
Return on assets %3.45.6 61.2%  
Return on equity %0.110.5 1.1%  
Return on capital %7.717.7 43.3%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m964300 321.8%   
Fx outflow Rs m6072,015 30.1%   
Net fx Rs m357-1,715 -20.8%   
CASH FLOW
From Operations Rs m1,34588 1,529.9%  
From Investments Rs m-2,256-94 2,409.8%  
From Financial Activity Rs m-1,200NA-  
Net Cashflow Rs m-2,111-6 37,029.8%  

Share Holding

Indian Promoters % 4.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.0 0.3 -  
FIIs % 1.4 15.7 8.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 9.1 1,034.1%  
Shareholders   20,807 12,856 161.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  AUROBINDO PHARMA  

Compare DR. DATSONS LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

CSB Bank IPO, October Passenger Vehicle Sales, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets witnessed buying interest during closing hours and ended on a positive note.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

MSTC IPO: Should You Bet on This State-Run E-Commerce Player? (IPO)

Mar 13, 2019

Should you subscribe to the IPO of MSPC Limited?

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS